Beidseitige Nivolumab-assoziierte Vogt-Koyanagi-Harada-artige Uveitis bei einem Patienten mit metastasiertem Nierenzellkarzinom

• Literatur

• 1 Dalvin LA, Shields CL, Orloff M. et al. Checkpoint inhibitors immune therapy: systemic indications and ophthalmic side effects. Retina 2018; 38: 1063-1078 doi:10.1097/IAE.0000000000002181
• 2 Heinzerling L, de Toni E, Schett G. et al. Checkpoint-Inhibitoren – Diagnostik und Therapie von Nebenwirkungen. Dtsch Arztebl Int 2019; 116: 119-126 doi:10.3238/arztebl.2019.0119
• 3 Fang T, Maberley DA, Etminan M. Ocular adverse events with immune checkpoint inhibitors. J Curr Ophthalmol 2019; 31: 319-322 doi:10.1016/j.joco.2019.05.002
• 4 Michel M, Sun MM, Levinson RD, Filipowicz A. et al. Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition. Ocul Immunol Inflamm 2020; 28: 217-227 doi:10.1080/09273948.2019.1577978
• 5 Obata S, Saishin Y, Teramura K. et al. Vogt-Koyanagi-Harada disease-like uveitis during nivolumab (anti-PD1 antibody) treatment for metastatic cutaneous malignant melanoma. Case Rep Ophthalmol 2019; 10: 67-74 doi:10.1159/000496682
• 6 Matsuo T, Yamasaki O. Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep 2017; 5: 694-700 doi:10.1002/ccr3.911
• 7 Mihailovic N, Dyballa J, Herz S. et al. Vogt-Koyanagi-Harada-artige Uveitis unter Immun-Checkpoint-Inhibitor-Therapie beim metastasierten malignen Melanom. Ophthalmologe 2020; 117: 467-471 doi:10.1007/s00347-019-00963-z
• 8 Liu X, Wang Z, Zhao C. et al. Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. Thorac Cancer 2020; 11: 810-818 doi:10.1111/1759-7714.13327
• 9 Brahmer JR, Lacchetti C, Schneider BJ. et al. Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714-1768 doi:10.1200/JCO.2017.77.6385
• 10 Shulgin B, Kosinsky Y, Helmlinger G. et al. Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis. Oncoimmunology 2020; 9: 1748982 doi:10.1080/2162402X.2020.1748982